Zydus Lifesciences (ZYDUSLIF) Q3 adjusted EBITDA for one offs was below our estimate led by lower GMs and higher R&D spend. We believe the company’s steady domestic franchise, strong balance ...

(Image Credits: Pixabay) Zydus Lifesciences Ltd on Wednesday reported a profit of Rs 1023.80 crore during the third quarter of FY25, posting a growth of 29.66 per cent in comparison to Rs 789.60 ...

Zydus Lifesciences’ (Zydus) Q3FY25 revenue was in line with our expectations, but lower sales of gRevlimid and gAsacol led to a miss in earnings. Higher sales of Mirabegron and new launches led ...

There is a fresh new set of detailed renders courtesy of case manufacturer Spigen. We can deduce a bit of info from the images. The button layout seems standard for Apple, though the Alert Slider ...

Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited) is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Zydus Wellness Ltd. is a Public Limited Listed company incorporated on 01/11/1994 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is ...

Zydus Lifesciences Q3 Earnings: Zydus Lifesciences reported a 30% YoY rise in Q3FY25 net profit to ₹1,023.5 crore, driven by strong US growth. Revenue increased 17% YoY, while EBITDA rose 26%. The ...

Zydus Lifesciences Ltd. reported US formulation sales that were ahead of expectations during the December quarter on Wednesday, February 5. Despite this, the stock has declined to the lows of the day.

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.